News

Article

Brammer Bio Announces Cell and Gene Therapy Manufacturing Site

Brammer Bio establishes late-phase development and commercial manufacturing facility for advanced cell and gene therapies in Lexington, MA.

Brammer Bio, a cell and gene therapy contract development and manufacturing organization, announced on June 8, 2016  plans to build-out a 50,000-sq-ft. facility for late phase development, including Phase III and commercial production, of viral vector-based and cell-based advanced therapies. The Lexington, MA, facility will be qualified and operational by Q2 of 2017.

After completing a merger with Florida Biologix in March 2016, the CDMO will further solidify its leading technical and operational supply position through the build-out of the Lexington, MA, facility.

Brammer Bio completed a merger with Florida Biologix in March 2016 and is building on Florida Biologix’s ten-year record of  manufacturing and testing to support clinical trials of advanced therapeutics, the company reports.

The addition of large-scale and late-stage manufacturing at the Lexington facility, in conjunction with the early clinical focus of the Florida location, will provide clients with the start-to-finish capability of manufacturing and testing advanced cell and gene therapies, according to a company statement.

Brammer Bio is looking to grow the Lexington workforce by up to 200, employing engineers and scientists, and specialists.

Brammer Bio is focused on providing clinical and commercial supply of autologous and allogeneic cell therapies, and viral vector products for in vivo and ex vivo therapeutic applications, along with process and analytical development, and regulatory support for large pharma and biotech clients.

Source: Brammer Bio

 

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content